Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial

OBJECTIVES: Canagliflozin (CANA), a kind of sodium-glucose cotransporter-2 (SGLT-2) inhibition, study in which the role of CANA monotherapy in polycystic ovary syndrome (PCOS) has been investigated, and it could become a novel option in the PCOS treatment. Nevertheless, trials focused on SGLT-2 comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiaqi, Xing, Chuan, Cheng, Xiangyi, He, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486461/
https://www.ncbi.nlm.nih.gov/pubmed/36147577
http://dx.doi.org/10.3389/fendo.2022.1003238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486461/
https://www.ncbi.nlm.nih.gov/pubmed/36147577
http://dx.doi.org/10.3389/fendo.2022.1003238

Ejemplares similares